SUBMIT PROPOSALS HERE
A core mission at BCM is to translate our collective scientific innovation into the benefit of our patients. As part of the BCM mission, the Therapeutic Innovation Center (THINC@BCM) is announcing a seed program to develop therapeutics against diseases of aberrant gene control. THINC is developing enabling platforms and collaborative teams to forge new therapies in the areas of transcription, chromatin, and RNA regulation across a variety of disease contexts. This seed program will support and enable BCM investigators to develop their therapeutic hypotheses towards therapeutic
development by leveraging THINC platforms and capabilities.
To learn more, please view the RFA and application template in the links below.